
-
Nanobiotix NasdaqGS:NBTX Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Location: 60 rue de Wattignies, Paris, 75012, France | Website: https://www.nanobiotix.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
196.9M
Cash
49.74M
Avg Qtr Burn
-4.888M
Short % of Float
0.30%
Insider Ownership
0.00%
Institutional Own.
12.15%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NBTXR3 +/- Cetuximab Details Head and neck cancer | Phase 3 Interim Update | |
JNJ-1900 (NBTXR3) Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
RT + NBTXR3 + Chemotherapy Details Esophageal cancer | Phase 1/2 Data readout | |
RT + NBTXR3 Details Cancer, Pancreatic cancer | Phase 1b Data readout | |
NBTXR3 + Anti-PD-1 Details Head and neck cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 1 Data readout | |
RT + NBTXR3 Details Cancer, Non-small cell lung carcinoma | Phase 1 Data readout | |
JNJ-1900 (NBTXR3) Details Pancreatic Cancer | Phase 1 Update |